Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

142 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Molecular Characterization of Neuroendocrine-like Bladder Cancer.
Batista da Costa J, Gibb EA, Bivalacqua TJ, Liu Y, Oo HZ, Miyamoto DT, Alshalalfa M, Davicioni E, Wright J, Dall'Era MA, Douglas J, Boormans JL, Van der Heijden MS, Wu CL, van Rhijn BWG, Gupta S, Grivas P, Mouw KW, Murugan P, Fazli L, Ra S, Konety BR, Seiler R, Daneshmand S, Mian OY, Efstathiou JA, Lotan Y, Black PC. Batista da Costa J, et al. Among authors: van rhijn bwg, van der heijden ms. Clin Cancer Res. 2019 Jul 1;25(13):3908-3920. doi: 10.1158/1078-0432.CCR-18-3558. Epub 2019 Apr 5. Clin Cancer Res. 2019. PMID: 30952638
Occult lymph node metastases in patients with carcinoma invading bladder muscle: incidence after neoadjuvant chemotherapy and cystectomy vs after cystectomy alone.
Mertens LS, Meijer RP, Meinhardt W, van der Poel HG, Bex A, Kerst JM, van der Heijden MS, Bergman AM, Horenblas S, van Rhijn BW. Mertens LS, et al. Among authors: van rhijn bw, van der heijden ms, van der poel hg. BJU Int. 2014 Jul;114(1):67-74. doi: 10.1111/bju.12447. Epub 2014 Jan 17. BJU Int. 2014. PMID: 24053889
The molecular background of urothelial cancer: ready for action?
van der Heijden MS, van Rhijn BW. van der Heijden MS, et al. Among authors: van rhijn bw. Eur Urol. 2015 Feb;67(2):202-3. doi: 10.1016/j.eururo.2014.07.017. Epub 2014 Aug 4. Eur Urol. 2015. PMID: 25103696 No abstract available.
ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy.
Groenendijk FH, de Jong J, Fransen van de Putte EE, Michaut M, Schlicker A, Peters D, Velds A, Nieuwland M, van den Heuvel MM, Kerkhoven RM, Wessels LF, Broeks A, van Rhijn BW, Bernards R, van der Heijden MS. Groenendijk FH, et al. Among authors: van rhijn bw, van den heuvel mm, van der heijden ms. Eur Urol. 2016 Mar;69(3):384-8. doi: 10.1016/j.eururo.2015.01.014. Epub 2015 Jan 27. Eur Urol. 2016. PMID: 25636205
Reply to Eliezer M. Van Allen, Levi A. Garraway and Jonathan E. Rosenberg's Letter to the Editor re: Floris H. Groenendijk, Jeroen de Jong, Elisabeth E. Fransen van de Putte, et al. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.01.014.
Groenendijk FH, Fransen van de Putte EE, van Rhijn BW, Bernards R, van der Heijden MS. Groenendijk FH, et al. Among authors: van rhijn bw, van der heijden ms. Eur Urol. 2015 Aug;68(2):e33-4. doi: 10.1016/j.eururo.2015.02.043. Epub 2015 Mar 13. Eur Urol. 2015. PMID: 25776733 No abstract available.
Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin.
van de Putte EE, Mertens LS, Meijer RP, van der Heijden MS, Bex A, van der Poel HG, Kerst JM, Bergman AM, Horenblas S, van Rhijn BW. van de Putte EE, et al. Among authors: van rhijn bw, van der heijden ms, van der poel hg. World J Urol. 2016 Feb;34(2):157-62. doi: 10.1007/s00345-015-1636-y. Epub 2015 Jul 17. World J Urol. 2016. PMID: 26184106
Perioperative treatment and radical cystectomy for bladder cancer--a population based trend analysis of 10,338 patients in the Netherlands.
Hermans TJN, Fransen van de Putte EE, Horenblas S, Lemmens V, Aben K, van der Heijden MS, Beerepoot LV, Verhoeven RH, van Rhijn BWG. Hermans TJN, et al. Among authors: van rhijn bwg, van der heijden ms. Eur J Cancer. 2016 Feb;54:18-26. doi: 10.1016/j.ejca.2015.11.006. Epub 2015 Dec 18. Eur J Cancer. 2016. PMID: 26707593
Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.
Pouessel D, Neuzillet Y, Mertens LS, van der Heijden MS, de Jong J, Sanders J, Peters D, Leroy K, Manceau A, Maille P, Soyeux P, Moktefi A, Semprez F, Vordos D, de la Taille A, Hurst CD, Tomlinson DC, Harnden P, Bostrom PJ, Mirtti T, Horenblas S, Loriot Y, Houédé N, Chevreau C, Beuzeboc P, Shariat SF, Sagalowsky AI, Ashfaq R, Burger M, Jewett MA, Zlotta AR, Broeks A, Bapat B, Knowles MA, Lotan Y, van der Kwast TH, Culine S, Allory Y, van Rhijn BW. Pouessel D, et al. Among authors: van rhijn bw, van der heijden ms, van der kwast th. Ann Oncol. 2016 Jul;27(7):1311-6. doi: 10.1093/annonc/mdw170. Epub 2016 Apr 18. Ann Oncol. 2016. PMID: 27091807 Free PMC article.
142 results